title: MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.
abstract: BACKGROUND
  The chronic airway infection with Pseudomonas aeruginosa (PA) is a risk factor for rapid disease progression in various chronic pulmonary diseases including cystic fibrosis or chronic obstructive pulmonary disease. Inhaled antibiotics are able to treat effectively such chronic airway infections, and MP-376 is currently in late-stage clinical development for such an indication.
  
  
  METHODS
  Review of the existing preclinical and clinical data on MP-376, with a focus on the efficacy and safety of the compound on chronic airways infections due to PA.
  
  
  CONCLUSIONS
  Chronic airways infection with PA represents a therapeutic challenge because of its own complex mechanisms of defense, because of the rapid development of antibiotic resistance and by the fact that systemic antibiotics are not always able to achieve appropriate concentrations at lung level. Inhaled antibiotics (tobramycin, aztreonam, etc.) represent optimal alternatives to their systemic homologs due to their better penetrability in the lungs and due to the lower systemic exposure. Inhaled levofloxacin which is currently investigated for chronic airways infection might be another possible antipseudomonal inhaled therapy.
authors.affiliation: University of Medicine and Pharmacy Grigore T Popa Iasi, Interdisciplinarity, Str. Universităţii nr 16, Iasi, 700115, Romania.
authors.forename: Doina
authors.initials: D
authors.lastname: Azoicai
authors.forename: Sabina Antonela
authors.initials: SA
authors.lastname: Antoniu
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin